Valuation: Precision BioSciences, Inc.

Market Cap 187M 164M 153M 141M 264M 17.94B 267M 1.82B 711M 8.86B 702M 687M 30.62B P/E 2026 *
-2.62x
P/E 2027 * -2.81x
Enterprise Value 187M 164M 153M 141M 264M 17.94B 267M 1.82B 711M 8.86B 702M 687M 30.62B EV / Sales 2026 *
9.95x
EV / Sales 2027 * 14.9x
Free-Float
93.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day-0.55%
1 week-1.49%
Current month-7.76%
1 month-0.55%
3 months+2.98%
6 months+75.54%
Current year+74.28%
1 week 7.07
Extreme 7.07
7.73
1 month 7.07
Extreme 7.07
9.62
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 2021-10-14
Chief Tech/Sci/R&D Officer 53 2006-01-25
Director of Finance/CFO 59 2020-12-31
Director TitleAgeSince
Chairman 68 2020-10-31
Director/Board Member 65 2020-03-09
Director/Board Member 67 2021-04-11
Date Insider Type Main position Quantity % Market Cap.
6/3/26 Free

Director

20,979 0.0872%
6/3/26 Free

Director

20,979 0.0872%
6/3/26 Free

Director

20,979 0.0872%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-1.49%+40.78%-57.30% 187M
-0.11%-1.03%-1.24%+10.62% 47.74B
-0.61%+4.26%+396.16%+647.20% 39.98B
0.00%+4.93%+11.81%+55.56% 36.23B
+2.48%+4.57%+7.05%-5.05% 35.59B
+0.62%+3.53%+5.41%+42.19% 27.91B
-0.17%+0.66% - - 16.71B
-2.00%+11.64%+31.71%+136.81% 16.45B
+0.03%-4.02%+2.20%+7.28% 13.21B
+1.82%+1.56%-9.75%-30.15% 12.93B
Average +0.14%+2.34%+53.79%+89.68% 24.69B
Weighted average by Cap. +0.25%+2.93%+74.02%+136.13%

Financials

2026 *2027 *
Net sales 18.81M 16.54M 15.39M 14.14M 26.54M 1.8B 26.89M 183M 71.46M 891M 70.61M 69.09M 3.08B 12.52M 11.01M 10.25M 9.41M 17.67M 1.2B 17.9M 122M 47.56M 593M 47M 45.99M 2.05B
Net income -77.69M -68.3M -63.58M -58.39M -110M -7.45B -111M -756M -295M -3.68B -292M -285M -12.72B -86.26M -75.83M -70.59M -64.83M -122M -8.27B -123M -839M -328M -4.08B -324M -317M -14.12B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
66
Date Price Change Volume
26-07-27 US$7.250 -0.55% 250,617
26-07-24 US$7.290 -0.55% 192,308
26-07-23 US$7.330 +0.14% 243,460
26-07-22 US$7.320 -3.94% 249,457
26-07-21 US$7.620 +3.53% 349,506
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.250USD
Average target price
29.60USD
Spread / Average Target
+308.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock